Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...

(n = 65) Randomized, discontinuation trial (part 2 of a two-part trial) Sorafenib Placebo Rate of progression-free survival 12 wk after randomization: 50% (sorafenib) vs. 18% (placebo) (p = 0.0077 ...